Dear investors,
In Rius Medical is an entrepreneur with a big vision who wants to create something less ordinary - something that matters, for all of us - a founder’s unshakeable intention to address a significant, pressing challenge on our planet and in our society! Products engineered with biotechnology present a collaborative space for Bioentrepreneurs and investors to address society big challenges of cancer, type 1 diabetes and other diseases. For Rius Medical, that is under ONE-Platform technology!
Yes, I agree that Rius Medical as a life science company is outside the investment scope of many investors. In general, Life Science investment is often perceived as high risk - the sector comprises companies that have an 85-95% failure rate on everything they attempt to invent. Even to achieve success takes about 10 to 12 years, and most biotech businesses do not have any measurable revenue for a long period of time. This view alone, yes! But that is not what Rius Medical does!
De-risking Rius Medical: 14 months to revenue by upgrading existing FDA/EMA approved biologics!
[1] Manufacture of Biologics - accelerate timelines for the development / manufacturing of molecules and disruptive technologies! The Lonza support to Bioqube Ventures www and ALSA Ventures www goes beyond due diligence of candidate biotechs by bringing tailored offering of advice and services to portfolio companies supporting de-risking early development and manufacturing of next-generation modalities. Developing and manufacturing these increasingly complex modalities require sophisticated facility design and expertise, which is often challenging to establish in-house (e.g. Rius Medical). Pnina Weitz, Global Head of Venture Capital Business Development and Relationship Management at Lonza, wants collaboration talks with Rius Medical this week. The collaboration aims to significantly increase the chances for the future success of these therapies by providing early de-risking and development and manufacturing services tailored to each molecule’s unique needs and properties.
[2] How do you see Axilium or Hadean Ventures if not Coparion PDF - a venture capital fund for young, German technology companies provided by ERP Special Fund, KfW Capital and European Investment Bank; making EUR 500,000 co-investment alongside Lead Investor EUR 500,000 investment inclusive of 20% refund from German Ministry for Economic Affairs and Climate Protection (BMWK) www? Yes, sharing the EUR 1 million requested funding between two investors. By the way, according to BMWK, the maximum “eligible investment amount for 20% refund” is EUR 500,000 per investor per year. Thus lowering the risk for investor(s) www. By December 2023, significant progress of Rius Medical is technology transfer deals to FR, Erytech Pharma (Enzyme L-Asparaginase) and USA, Travere Therapeutics parent company of CH, Orphan Technologies (Enzyme Thymidine phosphorylase) - both FDA/EMA approved biologics! Example: Travere Therapeutics (previously Retrophin) made an upfront payment of USD 90 million in cash at closing of the transaction. Orphan Technologies shareholders will remain eligible to receive up to USD 427 million in additional cash payments contingent upon the achievement of key milestones in the development and commercialisation of OT-58 www. [Encapsulation in 29 days half-life red blood cells from the patient's own blood, Phase 2 clinical trial until December 2022 at St George's, University of London www]. That’s right, Lead Investor co-investing with EUR 500,000 for 10% ownership in Rius Medical with EXIT option of EUR 5,2 million on two cell line products as technology transfer deals to third parties by December 2023! Thereafter CDMO Lonza as a partner to Health Solutions product line with red blood cells drug delivery of enzyme or antigen!
[3] Rius Medical Go-to-Market at reduced risk
For life sciences companies, regulatory compliance never becomes any less complex and stringent. Depending on the exact nature of the work and where business is done, multiple regulatory frameworks apply www. Nonetheless this does not apply to Rius Medical! For example Sanofi EUR 308 million buyout of Kiadis natural killer cell projects www is based on iPSC technology Kiadis acquired for nothing from Cytosen a year and a half ago. The move in November 2020 by Sanofi came just four months after the French company licensed one of Kiadis’s Cytosen-derived natural killer cell projects for EUR 17.5 million up front. Rius Medical out-licensing is EUR 20 million up front each on 2x red blood cells drug delivery of FDA/EMA approved enzymes (L-Asparaginase and Thymidine phosphorylase)! Sanofi and others shall handle the regulatory compliance!
The pharmaceuticals and life sciences industry is uniquely positioned to create value for society as its innovations lay the foundation for universal health and thus prosperity. COVID-19 emphasizes the central importance of the industry for society and the economy. I hereby wish to highlight key elements that Rius Medical is doing that might not be clearly depicted in the submitted Pitch Deck. What fits best for your investment strategy, yes that is what I would like to talk on a Zoom call.
Many thanks and warmest regards,
Denis
Denis Demarais
Founder and CEO
Email: denisdemarais@riusmedical.de